- Home
- KRUS vs URGN Comparison
KRUS vs URGN Comparison
Compare KRUS & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRUS
- URGN
- Stock Information
- Founded
- KRUS 2008
- URGN 2004
- Country
- KRUS United States
- URGN United States
- Employees
- KRUS N/A
- URGN N/A
- Industry
- KRUS Restaurants
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- KRUS Consumer Discretionary
- URGN Health Care
- Exchange
- KRUS Nasdaq
- URGN Nasdaq
- Market Cap
- KRUS 1.1B
- URGN 896.3M
- IPO Year
- KRUS 2019
- URGN 2017
- Fundamental
- Price
- KRUS $77.61
- URGN $17.75
- Analyst Decision
- KRUS Buy
- URGN Strong Buy
- Analyst Count
- KRUS 9
- URGN 8
- Target Price
- KRUS $94.56
- URGN $29.00
- AVG Volume (30 Days)
- KRUS 269.5K
- URGN 1.4M
- Earning Date
- KRUS 07-08-2025
- URGN 08-07-2025
- Dividend Yield
- KRUS N/A
- URGN N/A
- EPS Growth
- KRUS N/A
- URGN N/A
- EPS
- KRUS N/A
- URGN N/A
- Revenue
- KRUS $269,327,000.00
- URGN $94,238,000.00
- Revenue This Year
- KRUS $20.49
- URGN $39.80
- Revenue Next Year
- KRUS $20.15
- URGN $108.94
- P/E Ratio
- KRUS N/A
- URGN N/A
- Revenue Growth
- KRUS 18.76
- URGN 10.85
- 52 Week Low
- KRUS $40.03
- URGN $3.42
- 52 Week High
- KRUS $110.66
- URGN $21.02
- Technical
- Relative Strength Index (RSI)
- KRUS 42.11
- URGN 54.88
- Support Level
- KRUS $81.33
- URGN $17.07
- Resistance Level
- KRUS $86.46
- URGN $21.02
- Average True Range (ATR)
- KRUS 5.23
- URGN 1.31
- MACD
- KRUS -1.13
- URGN -0.21
- Stochastic Oscillator
- KRUS 7.97
- URGN 42.28
About KRUS Kura Sushi USA Inc.
Kura Sushi USA Inc is a technology-enabled restaurant concept serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. It offers several dishes, including Dashi Olive Salmon, Tomago, Sweet Shrimp, Tuna, Garlic Tuna Steak, and Salmon, among others.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.